SHANGHAI, CHINA - NOVEMBER 05: People visit the booth of Organon during the 7th China International Import Expo (CIIE) at the National Exhibition and Convention Center (Shanghai) on November 5, 2024 in Shanghai, China. The 7th China International Import Expo (CIIE) kicked off in Shanghai on November 5. (Photo by Tang Yanjun/China News Service/VCG via Getty Images) China News Service | China News Service | Getty Images India's Sun Pharmaceutical Industries will acquire New Jersey-based Organon & Co in an all-cash deal that values the U.S. company at $11.75 billion, including debt. The Indian generic drugmaker will acquire all outstanding shares of Organon for $14 apiece, according to an exchange filing Monday by Sun Pharmaceutical . "Following a comprehensive review of strategic alternatives, our Board determined that this all‑cash transaction offers compelling and immediate value to Organon stockholders," said Carrie Cox, executive chair at Organon, in the joint statement.…